Oishi Akio
Nippon Ganka Gakkai Zasshi. 2015 Nov;119(11):781-6.
The optimal treatment of polypoidal choroidal vasculopathy (PCV) is still undetermined. Photodynamic therapy (PDT) is effective for PCV but the Treatment effect declines after one year. While some reports show the efficacy of anti-vascular endothelial growth factor (VEGF) therapy for PCV, other reports show treatment-refractory cases. In this article, the author reviews the results of our multicenter randomized trial, conducted to compare the efficacy of PDT and ranibizumab in PCV patients. The results showed that ranibizumab is more effective in visual gain in two-year follow up. Central retinal thickness improved with both treatments and there was no difference between them. Our results provide evidence that ranibizumab is superior to PDT monotherapy for treatment of PCV in terms of visual acuity.
息肉状脉络膜血管病变（PCV）的最佳治疗方法仍未确定。光动力疗法（PDT）对PCV有效，但一年后治疗效果会下降。虽然一些报告显示抗血管内皮生长因子（VEGF）疗法对PCV有效，但其他报告显示存在治疗难治性病例。在本文中，作者回顾了我们进行的多中心随机试验的结果，该试验旨在比较PDT和雷珠单抗对PCV患者的疗效。结果显示，在两年的随访中，雷珠单抗在视力提高方面更有效。两种治疗方法均可改善视网膜中央厚度，且二者之间无差异。我们的结果提供了证据，表明在视力方面，雷珠单抗治疗PCV优于PDT单一疗法。
